What are immune checkpoint inhibitors? Immune checkpoint inhibitors are drugs that can inhibit the co-inhibitory immune checkpoint pathways , so that enhancing cancer immunity. Most of the immune checkpoint inhibitors are blocking antibodies. Sometimes fusion proteins can also act as immune checkpoint inhibitors. The immune checkpoint inhibitors have emerged as a mainstay in melanoma therapy, with potential roles in the treatment of renal cell carcinoma (RCC), non–small cell lung cancer (NSCLC), urothelial cancer, head and neck cancer, ovarian cancer, and various lymphomas et al. With many immune checkpoint molecules becoming targets of cancer therapy, numerous immune checkpoint inhibitors is underway.
|PD1 immune checkpoint inhibitors||Nivolumab, PembrolizumabIn, Pidilizumab, AMP-224|
|PD-L1 immune checkpoint inhibitors||BMS-936559, MEDI4736, MPDL3280A, Avelumab|
|CTLA-4 immune checkpoint inhibitors||Tremelimumab, Tremelimumab|
|B7-H3 immune checkpoint inhibitors||MGA271|
|IDO immune checkpoint inhibitors||Indoximod, INCB024360|
|KIR immune checkpoint inhibitors||Lirilumab|
|LAG3 immune checkpoint inhibitors||BMS-986016|
Howard (Jack) West, MD et al. Immune Checkpoint Inhibitors. JAMA Oncol. 2015;1(1):115.
Julie R. Brahmer et al. Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer. Cancer Immunol Res August 2013 1; 85.